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In this study, the mechanical properties of an implanted calcium phosphate (CaP) cement incorporated with 20wt% poly (DL-lactic-co-
glycolic acid) (PLGA) microparticles were investigated in a rat cranial defect. After 2, 4 and 8 weeks of implantation, implants were
evaluated mechanically (push-out test) and morphologically (Scanning Electron Microscopy (SEM) and histology). The results of the
push-out test showed that after 2 weeks the shear strength of the implants was 0.4470.44MPa (average7sd), which increased to
1.3471.05MPa at 4 weeks and ﬁnally resulted in 2.6072.78MPa at 8 weeks. SEM examination showed a fracture plane at the
bone–cement interface at 2 weeks, while the 4- and 8-week specimens created a fracture plane into the CaP/PLGA composites, indicating
an increased strength of the bone–cement interface. Histological evaluation revealed that the two weeks implantation period resulted in
minimal bone ingrowth, while at 4 weeks of implantation the peripheral PLGA microparticles were degraded and replaced by deposition
of newly formed bone. Finally, after 8 weeks of implantation the degradation of the PLGA microparticles was almost completed, which
was observed by the bone ingrowth throughout the CaP/PLGA composites.
On basis of our results, we conclude that the shear strength of the bone–cement interface increased over time due to bone ingrowth into
the CaP/PLGA composites. Although the bone–cement contact could be optimized with an injectable CaP cement to enhance bone
ingrowth, still the mechanical properties of the composites after 8 weeks of implantation are insufﬁcient for load-bearing purposes.
r 2006 Elsevier Ltd. All rights reserved.
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Calcium Phosphate (CaP) ceramics are widely used as
bone substitutes in dentistry, orthopedics and reconstruc-
tive surgery, because of their biocompatibility and osteo-
conductivity. Unfortunately, these ceramics are only
available as prefabricated blocks or granules. Prefabricated
blocks are difﬁcult to shape, resulting in poor ﬁlling of the
bone defect, while granules do not provide the dimensional
stability and can easily migrate into the surrounding tissue.
A solution for these problems can be CaP cement that can
be shaped according to the defect dimension and harden in
situ [1–9]. The injectable CaP cement as used in this studye front matter r 2006 Elsevier Ltd. All rights reserved.
omaterials.2006.05.022
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4657.
ess: j.jansen@dent.umcn.nl (J.A. Jansen).consists of a mixture of powder and liquid. The formed
paste hardens in situ as a result of the entanglement of the
newly formed crystals at body temperature. These cements
are highly compatible with soft and hard tissues because of
the apatitic nature of the setting reaction products.
However, calcium phosphate ceramics are known as slowly
biodegradable materials. Therefore, methods have been
developed to enhance tissue ingrowth and degradation rate
by increasing the porosity of the ceramics. Consequently,
the creation of macroporosity in CaP cement will increase
the degradation of the CaP cement as well as the ingrowth
of new bone tissue into the cement porosity [10–12]. In view
of this, cement composites were prepared in which poly
(DL-lactic-co-glycolic) acid (PLGA) microparticles were
incorporated [13–15]. The microparticles will be hydro-
lyzed in vivo and as a consequence create macroporosity.
However, the in vivo degradation rate of the PLGA
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such as molecular weight, particle size and structure [16].
Therefore, the inclusion of PLGA microparticles into CaP
cement will result in increased macroporosity after
degradation of the particles. The degradation rate of the
microparticles is generally faster than the surrounding CaP
cement. Additionally, the incorporation of degradable
microparticles can be used to allow drug and growth
factor delivery [15,17].
In vitro research on the mechanical properties of highly
porous biodegradable cement composites by others showed
compressive strength and a modulus of elasticity compar-
able to trabecular bone [18–29]. On the other hand, a
previous study by Ruhe´ et al. [15] on the mechanical
strength of CaP/PLGA cement composite scaffolds in vitro
showed that the initial strength of this composite scaffold is
signiﬁcantly lower than for CaP cement alone. The creation
of porosity is associated with a loss in mechanical strength
of the cement material; this appears to make the material
less suitable for use under loaded conditions. Alternatively,
the initial decrease in mechanical strength could be
compensated by the excellent bone biocompatibility of
the material. This allows a fast ingrowth of bone into the
cement porosity.
Therefore, the aim of our study is to prove that bone
ingrowth results in an increase of mechanical strength of
the macroporous cement.
2. Materials and methods
2.1. Substrates
CaP cement (Calcibons, Merck biomaterial GmbH, Darmstadt,
Germany) was used for the preparation of the implants. The chemical
composition of this cement is 62.5% a-TCP, 26.8% CaHPO4, 8.9%
CaCO3 and 1.8% PHA (a-TCP is a tri-calcium phosphate, PHA is
precipitated hydroxyapatite). An aqueous solution of 1% Na2HPO4 was
used as the liquid component. The ideal liquid/powder ratio for clinical
applications has shown to be 0.35ml/g. Before usage, the cement powder
was sterilized by g-radiation with 25 kGy (Isotron B.V., Ede, The
Netherlands). The cement liquid was ﬁlter-sterilized through a sterile
0.2mm ﬁlter.
2.2. PLGA microparticles
PLGA (Purasorbs, Purac, Gorinchem, The Netherlands) microparti-
cles were prepared using a (water/oil/water) double emulsion solvent
evaporation technique. The microparticles were produced by solving 1.0 g
PLGA in 4ml of dichloromethane (DCM) inside a glass tube. After
dissolution, 500ml deionized water was added to this mixture and
emulsiﬁed for 60 s on a vortexer. Subsequently, 6ml 0.3% aqueous
poly(vinyl alcohol) (PVA) solution was added and vortexed for another
60 s to produce the second emulsion. After vortexing, the content of the
glass tube was transferred to a stirred 1000ml beaker and another 394ml
of 0.3% PVA was added slowly. This was directly followed by adding
400ml of a 2% isopropylic alcohol (IPA) solution. The suspension was
stirred for 1 h. After stirring, the microparticles were allowed to settle for
15min and the solution was decanted. The suspension left was centrifuged,
and the clear solution at the top was decanted. Then 5ml of deionized
water was added, the microparticles were washed, centrifuged and the
solution was aspirated. Finally, the microparticles were frozen, freeze-dried for 24 h and stored under argon at 20 1C. The microparticle sizes
varied between 5 and 120mm with an average size of 33 mm. This was
determined with an optical microscope (Leica DM Microscope system,
Microsystems AG, Wetzlar, Germany) after microparticles were sus-
pended in deionized water. Digital image software (Leica Qwins, Leica
Microsystems AG, Wetzlar, Germany) was applied to determine the
microparticle size distribution of the PLGA microparticles.
2.3. CaP/PLGA microparticle composites
CaP/PLGA cement composites were prepared by adding PLGA
microparticles to the CaP cement powder in a weight ratio of 20–80%,
respectively. Then, 350ml cement liquid (1wt% aqueous solution of
Na2HPO4) was added to 1000mg of the CaP/PLGA mixture in a 2ml
syringe (Becton Dickinson, Alphen a/d Rijn, The Netherlands). The
syringe was closed with an injection plunger and placed in a mixing
apparatus (Silamat, Ivoclar Vivadent AG, Schaan, Liechtenstein). After
mixing for 15 s, the plunger was removed and the composite was injected
in Teﬂon molds to ensure a standardized shape of the specimens. The disks
(5mm in diameter and 2mm in height) were removed from the molds after
setting of the cement at 37 1C for 1 h. The total porosity 67% was
calculated by dividing the weight of CaP disks through the weight of CaP/
PLGA disks, after the samples were placed in a furnace at 650 1C for 2 h to
burn out the PLGA microparticles.
2.4. Surgery
Twenty-four male Wistar rats (250 g) were used for a cranial study.
Each rat received one implant. The implantation periods were 2, 4, and 8
weeks, respectively (n ¼ 8 for all implantation periods). National guide-
lines for the care and use of laboratory animals were respected. Surgery
was performed under general inhalation anesthesia induced by 5%
isoﬂurane, and maintained with 2.5% isoﬂurane by a non-rebreather
mask. The rats were monitored with an oxy-pulse meter during surgery.
To minimize postoperative pain, Fentanyls (3ml/kg intraperitoneal) was
administered preoperatively and buprenorﬁne (Temgesics) (0.05mg/kg
subcutaneous) for 2 days postoperatively.
After anesthesia, the rats were immobilized on their abdomen and the
skull was shaved and disinfected with povidone–iodine. A longitudinal
incision was made down to the periosteum from the nasal bone to the
occipital protuberance, and soft tissues were sharp dissected to visualize
the cranial periosteum. Subsequently, a midline incision was made in the
periosteum, and the periosteum was undermined and lifted off the parietal
skull. The pain was minimized by dripping lidocaine at the periosteum
before incision. A full thickness bone defect was created in the parietal
cranium, left of the sagittal suture, to avoid complications with the sagittal
sinus. A hollow trephine bur (ACE Dental Implant Systems, Portugal)
with an outer diameter of 5.1mm in a dental handpiece was used to create
the defect. The bone defect was carefully drilled under continuous cooling
with physiologic saline and without damaging of the underlying dura.
After that, the created bone segment was carefully removed. Following
insertion of the implants, the periosteum was closed using non-resorbable
Prolenes 5-0 suture material. Subsequently, skin was closed using
resorbable Vicryls 4-0 sutures.
The animals were housed individually in cages. The proper intake of
ﬂuids and food was monitored during the ﬁrst 5 days post-operatively.
Further, the animals were observed for signs of pain, infection and proper
activity. After 2, 4 or 8 weeks of surgery rats were sacriﬁced by an
overdose of CO2.
2.5. Mechanical testing, i.e. push-out test
To determine the shear strength of the porous implants after 2, 4 and 8
weeks of implantation, a push out-test [34,35] was performed in a
mechanical testing bench (MTS 858 Mini Bionix II, Gouda, The
Netherlands). After sacriﬁcing, the implants with their surrounding tissue
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Fig. 1. Box–Whisker plot of the push-out results from the 2, 4 and 8 week
implantation periods. The box shows the ﬁrst and third quartile with the
median value in between and the whiskers are representing the minimum
and maximum values.
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Subsequently, each specimen was ﬁxated on a support jig with a hole
0.4mm larger than the implant diameter (5.1mm) to minimize the effect
of the test condition on the push-out results. This support jig enabled
the application of a vertical force (at a constant displacement speed of
0.5mm/min) on the CaP/PLGA disks. When the peak force was reached
(representing implant loosening), the test was immediately stopped to
ensure minimal displacement of the disk. The shear strength of the
bone–cement interface was calculated by dividing the push-out force (N)
by p (pi) times the disc diameter (mm) times the cranial thickness (mm).
2.6. Scanning electron microscopy (SEM)
Following the push-out test, specimens were ﬁxed in 10% formalin
solution, dehydrated in a graded series of ethanol, and embedded in epoxy
resin (Epoﬁxs, Struers, Rødovre, Denmark). After polishing, the speci-
mens were sputter-coated with gold, and examined with SEM (Jeol 6310
scanning electron microscope, Boston, MA, USA) to determine the
fracture plane of the mechanically tested implants (e.g. in the cement, at
the interface bone–cement, in the surrounding bone). SEM was performed
at the Microscopic Imaging Center (MIC) of the Nijmegen Center for
Molecular Life Sciences (NCMLS), The Netherlands.
2.7. Histology
After SEM examination, 10 mm-thick sections were prepared of the
specimens embedded in epoxy resin in a direction transverse to the implant
his axis using a sawing microtome technique. The sections were stained
with methylene blue (cores) and basic fuchsin (collagen, bone), and
investigated with a light microscope (Leica Microsystems AG, Wetzlar,
Germany) to examine the bone–cement interface and possible bone
ingrowth.
2.8. Statistical analyses
Statistical analyses were performed with GraphPads Instat 3.05
software (GraphPad Software Inc., San Diego, CA, USA) using one-
way analyses of variance (ANOVA) with a Tukey multiple comparison
post test.
3. Results
3.1. Push-out test
The results of the push-out test (Fig. 1) demonstrated
that after 2 weeks of implantation the push-out values
ranged from 0.18 to 1.28MPa, which increased from 0.37
to 3.12MPa at 4 weeks and ﬁnally got to a range varying
from 0.21 to 8.12MPa. Calculating these push-out results
into the shear strength of the bone–cement interface
resulted in averages (7standard deviation) of 0.447
0.44MPa at 2 weeks, which increased to 1.3471.05MPa
at 4 weeks and ﬁnally resulted in 2.6072.78MPa at 8
weeks. However, the differences between the three implan-
tation groups were not signiﬁcant.
3.2. SEM examination
SEM examination (Fig. 2(A)) showed a fracture plane at
the bone–cement interface at 2 weeks. The 4-week implants
showed a fracture plane, which was found at the bone–
cement interface and into the CaP/PLGA compositesas well (Fig. 2(B)). The 8-week implants demonstrated
only fractures throughout the CaP/PLGA composites
(Fig. 2(C)).3.3. Histology
Histological evaluation (Fig. 3(A and B)) showed that
the 2 weeks implantation period resulted in minimal bone
ingrowth from the cranial bone into the implants. At four
weeks of implantation, the peripheral PLGA microparti-
cles were degraded and replaced by newly formed bone.
Further, a small layer of bone was present at the cerebral
side of the implants. Fibrous tissue was observed between
the cranial bone and the CaP/PLGA composites, especially
when no close contact of cranial bone with the implant was
observed. After 8 weeks of implantation, almost all PLGA
microparticles were degraded and bone deposition was
observed throughout the composites. The CaP cement was
starting to degrade as indicated by loss of integrity of the
implant and by the replacement of the cement with newly
formed bone (Fig. 3(C and D)). Nonetheless, not all of the
implants showed good bone ingrowth, some implants
showed ﬁbrous tissue between the cranial bone with the
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Fig. 2. SEM examination of a 2 (A), 4 (B) and 8 (C) week implantation period, respectively. CaP ¼ calcium phosphate cement; B ¼ cranial bone;
D ¼ degradated PLGA microparticle; F ¼ fracture plane; I ¼ bone–cement interface; N ¼ newly formed bone; P ¼ PLGA microparticle.
Fig. 3. Histology of a two (A and B) and 8 (C and D) week implantation period, respectively. B ¼ cranial bone; I ¼ bone–cement interface (ﬁlled with
ﬁbrous tissue); N ¼ newly formed bone.
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bone and implant was observed.
4. Discussion
FDA regulations concerning medical devices state that
bone ﬁllers should be investigated on their mechanicalproperties to gain approval for clinical usage. The
biomechanical testing should demonstrate the quality of
the newly formed bone (Class II Special Controls Guidance
Document: Dental bone-grafting material devices). There-
fore a push-out test was used to evaluate the shear strength
of the bone–cement interface. Results of the push-out test
showed that shear strength of the implants increased
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specimens with the highest shear strength still maintained
the bone–cement bond, although the composites were
fractured. This indicated that the 8-week implantation
results were an underestimation of the real shear strength
value. Nevertheless, these results conﬁrmed our hypothesis
that degradation of PLGA microparticles resulted in
macroporosity of the CaP cement, followed by replacement
of newly formed bone, and as a consequence in an increase
of mechanical properties. This effect was also described in
other studies involving CaP cement [30,31].
To avoid complications with the sagittal sinus, the
cranial defect size used in this study was not a critical size
defect [32,33], but, this was not a restriction for the aim of
the study, i.e. the mechanical properties of CaP cement
incorporated with PLGA microparticles. Also, pre-set
CaP/PLGA implants were used in this study, because the
rat cranial defect is not suitable to inject composites.
Furthermore, problems with the ﬁnal setting time were still
present in vivo, which could result in non-standardized
implants.
In this study, results from the push-out test assumed an
equal load distribution at the bone–cement interface.
However, test boundary conditions can signiﬁcantly
inﬂuence the load distribution [34]. Nevertheless, these
push-out results are still an approximation of the real
bone–cement interface shear strength.
Interestingly, large shear strength variations between
samples from the same implantation period were observed.
This variation can be explained by the differences in
random distribution of the PLGA microparticles in the
CaP cement. Accumulation of PLGA microparticles can
result in relatively weak spots inside the composite,
resulting in reduced push-out strength values. Large varia-
tions of the push-out test can also be due to differences
between rats, surgical techniques, surface roughness or
implant locations [35]. Some implants were press-ﬁtted into
the cranial defect, where others were less press-ﬁtted. More
bone formation was observed with the histological sections
when close contact between implant and bone was
detected, compared to implants with less contact between
the implant and the cranial bone. Dhert et al. reported that
mechanical test results can be inﬂuenced by implant
ﬁxation [34]. In the future, this problem can be solved by
applying CaP/PLGA composites as an injectable compo-
site and not as pre-set disks.
For this study, CaP/PLGA composites with weight
ratios of 80–20%, respectively were used. This composition
was chosen based on previous research with similar CaP/
PLGA cement composites. Previous in vitro research
showed that PLGA microparticles started to degrade from
week 6 and degradation was completed at week 12.
Degradation of the PLGA microparticles resulted in
reduction of the mechanical properties of the implants.
This was also indicated in in vitro compression tests, in
which the composites had an initial 30MPa strength which
was reduced to 4.3MPa at 12 weeks [36]. Therefore, basedon the in vitro compression tests and the results of the
push-out test performed in the present study, we concluded
that the CaP/PLGA composites are not suitable for load
bearing purposes, since it was reported that the shear
strength of compact bone ranges from 53.1 to 70MPa [37].
Lowering the PLGA ratio in the composites could be
considered to increase the mechanical properties of the
implants, but this reduces the amount of bone ingrowth in
the composites.
Other factors, which inﬂuence the mechanical properties
of the composites, are the total amount of porosity, pore
size and pore structure [38]. These factors should be
appropriate to allow cell ingrowth and transport of
nutrients and waste [39]. In this study, the total porosity
of the CaP/PLGA composites was approximately 67%,
with microparticle sizes varying from 5 to 120 mm with an
average diameter of 33 mm. These microparticle sizes were a
result of the forcefulness of vortexing during the double
emulsion process, which was crucial for the eventual size
distribution. The size distribution of the microparticles was
measured afterwards. This could also explain why different
microparticle sizes, varying from 0.017mm to 0.1mm, were
used in previous studies [10,14,15] and this study. However,
PLGA microparticles were added based on their weight,
not on their size, so the amount of PLGA in the implants
remained the same, independent of the microparticle size.
Nevertheless, the microparticles in our study create a less
than optimal pore size for bone ingrowth as described by
literature. Research by others on the optimal pore size of
porous ceramics varied between 50 and 400 mm [38,40,41].
Although, the average diameter is much smaller than the
reported optimal size, there is still abundant ingrowth of
bone in our specimens. This suggests that the optimal pore
sizes may be much smaller for CaP cement than for
materials with less favorable biological interactions.
Further, porosity greatly inﬂuences the rate of degrada-
tion of the CaP cement. It was reported that degradation of
macroporous CaP cement can reach up to 80% after 10
weeks [10]. However, crystallinity, density, pH in the
implant region, animal model and implantation site also
contribute to the rate of degradation [40]. Therefore,
complete degradation of the CaP cement varies between
weeks to years depending on the physicochemical proper-
ties being used [42–45].
The increasing shear strength of the bone–cement
interface over time was also conﬁrmed by SEM examina-
tion, which showed a fracture plane at the bone–cement
interface at 2 weeks, while the 4- and 8-week specimens
created a fracture plane into the CaP/PLGA composites,
indicating an increased strength of the bone–cement
interface. Histological evaluation conﬁrmed that the 2
weeks implantation period resulted in minimal bone
ingrowth. At 4 weeks of implantation, the peripheral
PLGA microparticles were degraded and replaced by newly
formed bone. Further, a small layer of bone was present at
the cerebral side of the implants bridging the entire defect.
Fibrous tissue was observed between the cranial bone and
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contact was observed. After 8 weeks of implantation,
almost all PLGA microparticles were degraded and bone
deposition was observed throughout the composites. SEM
and histology revealed that bone formation started at the
defect edges and cerebral side of the implant and proceeded
into the macropores which were created by the degradated
PLGA microparticles. This observation agrees with pre-
vious in vivo experiments [10,14] which showed that this
CaP cement showed excellent bone compatibility, but full
comparison with both studies is not possible, since different
composite formulations, different implants sizes and longer
implantation periods were used.
5. Conclusions
On basis of our results, we conclude that the shear
strength of the bone–cement interface increased over time
due to bone ingrowth into the CaP/PLGA composites.
Although the bone–cement contact could be optimized
with an injectable CaP cement to enhance bone ingrowth,
the mechanical properties of the composites after 8 weeks
of implantation are still insufﬁcient for load-bearing
purposes.
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